Last reviewed · How we verify
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate (Menactra®: Polysaccharide Diphtheria Toxoid Conjugate) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Menactra®: Polysaccharide Diphtheria Toxoid Conjugate TARGET | Menactra®: Polysaccharide Diphtheria Toxoid Conjugate | Sanofi Pasteur, a Sanofi Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Menactra®: Polysaccharide Diphtheria Toxoid Conjugate CI watch — RSS
- Menactra®: Polysaccharide Diphtheria Toxoid Conjugate CI watch — Atom
- Menactra®: Polysaccharide Diphtheria Toxoid Conjugate CI watch — JSON
- Menactra®: Polysaccharide Diphtheria Toxoid Conjugate alone — RSS
Cite this brief
Drug Landscape (2026). Menactra®: Polysaccharide Diphtheria Toxoid Conjugate — Competitive Intelligence Brief. https://druglandscape.com/ci/menactra-polysaccharide-diphtheria-toxoid-conjugate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab